Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 8/20 | 0.42 |
| ▸ | CA2 | P00918 | 8/20 | 0.42 |
| ▸ | MMP1 | P03956 | 5/20 | 0.40 |
| ▸ | MMP2 | P08253 | 5/20 | 0.40 |
| ▸ | MMP9 | P14780 | 5/20 | 0.40 |
| ▸ | MMP8 | P22894 | 5/20 | 0.40 |
| ▸ | MMP13 | P45452 | 5/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1345635 | 0.86 | MAPT (0.40) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL2261974 | 0.72 | CA2 (0.68) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5916339 | 0.72 | CA1 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28860429 | 0.70 | CA2 (0.44) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL30096771 | 0.69 | CA1 (0.39) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL28498811 | 0.69 | CA1 (0.41) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL25298036 | 0.69 | CA2 (0.44) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1593152 | 0.69 | CA1 (0.37) | CA1CA2MMP1MMP2MMP9 | |
| Ammonia Solution, Strong SCHEMBL28221452 | 0.68 | CA2 (0.43) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6479936 | 0.68 | CA2 (0.45) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705050-B2 | Amides, useful in the inhibition of IL-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| EP-1255726-B1 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-11 | — | — | EP | disclosed |
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181073-A1 | Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils | CXCL8, MMP8, CCR8 | CA1 3350/4885CA2 2998/4885MMP1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.